Specifying the Anti-inflammatory Effects of Ziltivekimab

PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 3, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

October 1, 2026

Conditions

AtherosclerosisInflammation

Interventions

DRUG

Ziltivekimab

Monoclonal antibody targeting IL-6

DRUG

Placebo

Trial Locations (1)

RECRUITING

Amsterdam UMC, location AMC, Amsterdam

All Listed Sponsors

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER